|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Li Z and Kang Y: Emerging therapeutic
targets in metastatic progression: A focus on breast cancer.
Pharmacol Ther. 161:79–96. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cai WL, Huang WD, Li B, Chen TR, Li ZX,
Zhao CL, Li HY, Wu YM, Yan WJ and Xiao JR: microRNA-124 inhibits
bone metastasis of breast cancer by repressing Interleukin-11. Mol
Cancer. 17:92018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Coleman RE: Bisphosphonates: Clinical
experience. Oncologist. 9(Suppl 4): 14–27. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
D'Oronzo S, Gregory W, Nicholson S, Chong
YK, Brown J and Coleman R: Natural history of stage II/III breast
cancer, bone metastasis and the impact of adjuvant zoledronate on
distribution of recurrences. J Bone Oncol. 28:1003672021.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tanaka R, Yonemori K, Hirakawa A,
Kinoshita F, Takahashi N, Hashimoto J, Kodaira M, Yamamoto H,
Yunokawa M, Shimizu C, et al: Risk factors for developing
skeletal-related events in breast cancer patients with bone
metastases undergoing treatment with bone-modifying agents.
Oncologist. 21:508–513. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Coleman RE and Rubens RD: The clinical
course of bone metastases from breast cancer. Br J Cancer.
55:61–66. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lu X and Kang Y: Organotropism of breast
cancer metastasis. J Mammary Gland Biol Neoplasia. 12:153–162.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Taube T, Elomaa I, Blomqvist C, Beneton MN
and Kanis JA: Histomorphometric evidence for osteoclast-mediated
bone resorption in metastatic breast cancer. Bone. 15:161–166.
1994. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Weidle UH, Birzele F, Kollmorgen G and
Rüger R: Molecular mechanisms of bone metastasis. Cancer Genomics
Proteomics. 13:1–12. 2016.
|
|
11
|
Siclari VA, Guise TA and Chirgwin JM:
Molecular interactions between breast cancer cells and the bone
microenvironment drive skeletal metastases. Cancer Metastasis Rev.
25:621–633. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sutherland A, Forsyth A, Cong Y, Grant L,
Juan TH, Lee JK, Klimowicz A, Petrillo SK, Hu J, Chan A, et al: The
role of prolactin in bone metastasis and breast cancer
cell-mediated osteoclast differentiation. J Natl Cancer Inst.
108:1082015.
|
|
13
|
Hussein O, Tiedemann K and Komarova SV:
Breast cancer cells inhibit spontaneous and bisphosphonate-induced
osteoclast apoptosis. Bone. 48:202–211. 2011. View Article : Google Scholar
|
|
14
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Browne G, Taipaleenmäki H, Stein GS, Stein
JL and Lian JB: MicroRNAs in the control of metastatic bone
disease. Trends Endocrinol Metab. 25:320–327. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ell B, Mercatali L, Ibrahim T, Campbell N,
Schwarzenbach H, Pantel K, Amadori D and Kang Y: Tumor-induced
osteoclast miRNA changes as regulators and biomarkers of osteolytic
bone metastasis. Cancer Cell. 24:542–556. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Usmani A, Shoro AA, Shirazi B, Memon Z and
Hussain M: MiR-16: A novel hereditary marker in breast cancer and
their offspring. J Pak Med Assoc. 67:446–450. 2017.PubMed/NCBI
|
|
19
|
Sui Y, Zhang X, Yang H, Wei W and Wang M:
MicroRNA-133a acts as a tumour suppressor in breast cancer through
targeting LASP1. Oncol Rep. 39:473–482. 2018.
|
|
20
|
Zhang L, Li H, Zang Y and Wang F: NLRP3
inflammasome inactivation driven by miR 223 3p reduces tumor growth
and increases anticancer immunity in breast cancer. Mol Med Rep.
19:2180–2188. 2019.PubMed/NCBI
|
|
21
|
Sugatani T and Hruska KA: MicroRNA-223 is
a key factor in osteoclast differentiation. J Cell Biochem.
101:996–999. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sugatani T and Hruska KA: Impaired
micro-RNA pathways diminish osteoclast differentiation and
function. J Biol Chem. 284:4667–4678. 2009. View Article : Google Scholar :
|
|
23
|
Xu XY, Guo C, Yan YX, Guo Y, Li RX, Song M
and Zhang XZ: Differential effects of mechanical strain on
osteoclastogenesis and osteoclast-related gene expression in
RAW264.7 cells. Mol Med Rep. 6:409–415. 2012.PubMed/NCBI
|
|
24
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
25
|
Modderman WE, Tuinenburg-Bol Raap AC and
Nijweide PJ: Tartrate-resistant acid phosphatase is not an
exclusive marker for mouse osteoclasts in cell culture. Bone.
12:81–87. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Faul F, Erdfelder E, Lang AG and Buchner
A: G*Power 3: A flexible statistical power analysis program for the
social, behavioral, and biomedical sciences. Behav Res Methods.
39:175–191. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Okada Y, Ueno H, Katagiri M, Oneyama T,
Shimomura K, Sakurai S, Mataga I, Moride M and Hasegawa H:
Experimental study of antiangiogenic gene therapy targeting VEGF in
oral cancer. Odontology. 98:52–59. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Mishra S, Tang Y, Wang L, deGraffenried L,
Yeh IT, Werner S, Troyer D, Copland JA and Sun LZ: Blockade of
transforming growth factor-beta (TGFβ) signaling inhibits
osteoblastic tumorigenesis by a novel human prostate cancer cell
line. Prostate. 71:1441–1454. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Papachristou DJ, Basdra EK and
Papavassiliou AG: Bone metastases: Molecular mechanisms and novel
therapeutic interventions. Med Res Rev. 32:611–636. 2012.
View Article : Google Scholar
|
|
30
|
Kingsley LA, Fournier PG, Chirgwin JM and
Guise TA: Molecular biology of bone metastasis. Mol Cancer Ther.
6:2609–2617. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hofbauer LC, Rachner TD, Coleman RE and
Jakob F: Endocrine aspects of bone metastases. Lancet Diabetes
Endocrinol. 2:500–512. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Mundy GR: Metastasis to bone: Causes,
consequences and therapeutic opportunities. Nat Rev Cancer.
2:584–593. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
33
|
Steeg PS: Tumor metastasis: Mechanistic
insights and clinical challenges. Nat Med. 12:895–904. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Roodman GD: Biology of osteoclast
activation in cancer. J Clin Oncol. 19:3562–3571. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Thomas RJ, Guise TA, Yin JJ, Elliott J,
Horwood NJ, Martin TJ and Gillespie MT: Breast cancer cells
interact with osteoblasts to support osteoclast formation.
Endocrinology. 140:4451–4458. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Tulotta C and Ottewell P: The role of
IL-1B in breast cancer bone metastasis. Endocr Relat Cancer.
25:R421–R434. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Fili S, Karalaki M and Schaller B:
Mechanism of bone metastasis: The role of osteoprotegerin and of
the host-tissue microenvironment-related survival factors. Cancer
Lett. 283:10–19. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Palmqvist P, Persson E, Conaway HH and
Lerner UH: IL-6, leukemia inhibitory factor, and oncostatin M
stimulate bone resorption and regulate the expression of receptor
activator of NF-kappa B ligand, osteoprotegerin, and receptor
activator of NF-kappa B in mouse calvariae. J Immunol.
169:3353–3362. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Sunyer T, Lewis J, Collin-Osdoby P and
Osdoby P: Estrogen's bone-protective effects may involve
differential IL-1 receptor regulation in human osteoclast-like
cells. J Clin Invest. 103:1409–1418. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wu X, Zeng R, Wu S, Zhong J, Yang L and Xu
J: Comprehensive expression analysis of miRNA in breast cancer at
the miRNA and isomiR levels. Gene. 557:195–200. 2015. View Article : Google Scholar
|
|
41
|
Calin GA and Croce CM: MicroRNA-cancer
connection: The beginning of a new tale. Cancer Res. 66:7390–7394.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Schwarzenbach H, Hoon DS and Pantel K:
Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev
Cancer. 11:426–437. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Chen WS, Leung CM, Pan HW, Hu LY, Li SC,
Ho MR and Tsai KW: Silencing of miR-11 and miR-133a2 cluster
expression by DNA hypermethylation in colorectal cancer. Oncol Rep.
28:1069–1076. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Shi W, Tang T, Li X, Deng S, Li R, Wang Y,
Wang Y, Xia T, Zhang Y, Zen K, et al: Methylation-mediated
silencing of miR-133a-3p promotes breast cancer cell migration and
stemness via miR-133a-3p/MAML1/DNMT3A positive feedback loop. J Exp
Clin Cancer Res. 38:4292019. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Fabris L, Berton S, Citron F, D'Andrea S,
Segatto I, Nicoloso MS, Massarut S, Armenia J, Zafarana G, Rossi S,
et al: Radiotherapy-induced miR-223 prevents relapse of breast
cancer by targeting the EGF pathway. Oncogene. 35:4914–4926. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Wang X, Tong Z and Liu H: MiR-223-3p
targeting epithelial cell transforming sequence 2 oncogene inhibits
the activity, apoptosis, invasion and migration of MDA-MB-468
breast cancer cells. OncoTargets Ther. 12:7675–7684. 2019.
View Article : Google Scholar
|
|
47
|
McGuire A, Brown JA and Kerin MJ:
Metastatic breast cancer: The potential of miRNA for diagnosis and
treatment monitoring. Cancer Metastasis Rev. 34:145–155. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Hamam R, Hamam D, Alsaleh KA, Kassem M,
Zaher W, Alfayez M, Aldahmash A and Alajez NM: Circulating
microRNAs in breast cancer: Novel diagnostic and prognostic
biomarkers. Cell Death Dis. 8:e30452017. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Di Mauro V, Crasto S, Colombo FS, Di
Pasquale E and Catalucci D: Wnt signalling mediates miR-133a
nuclear re-localization for the transcriptional control of Dnmt3b
in cardiac cells. Sci Rep. 9:93202019. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Liu N, Bezprozvannaya S, Williams AH, Qi
X, Richardson JA, Bassel-Duby R and Olson EN: microRNA-133a
regulates cardiomyocyte proliferation and suppresses smooth muscle
gene expression in the heart. Genes Dev. 22:3242–3254. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Roffel MP, Bracke KR, Heijink IH and Maes
T: miR-223: A key regulator in the innate immune response in asthma
and COPD. Front Med (Lausanne). 7:1962020. View Article : Google Scholar
|
|
52
|
Ye D, Zhang T, Lou G and Liu Y: Role of
miR-223 in the pathophysiology of liver diseases. Exp Mol Med.
50:1–12. 2018. View Article : Google Scholar
|
|
53
|
Wang M, Xia F, Wei Y and Wei X: Molecular
mechanisms and clinical management of cancer bone metastasis. Bone
Res. 8:302020. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Fares J, Fares MY, Khachfe HH, Salhab HA
and Fares Y: Molecular principles of metastasis: A hallmark of
cancer revisited. Signal Transduct Target Ther. 5:282020.
View Article : Google Scholar : PubMed/NCBI
|
